Allozyne, Inc. was founded to commercialize proprietary technologies developed in the laboratories of Dr. David Tirrell and Dr. William Goddard III., at the California Institute of Technology. These technologies will enable the company to improve the efficacy of protein-based therapeutics. This is achieved by applying a rapid and consistent approach to specifically modifying recombinant proteins, and has broad utility in developing improved therapeutic proteins including monoclonal antibodies.
 
The Allozyne approach enables the manufacturing of proteins into which non-natural amino acids may be incorporated.  These are chemical structures that are similar to yet distinct from the naturally occurring amino acid building blocks of protein.  The type and specific location of the non-natural amino acid used can be optimized to improve the potency, tolerability and pharmacology of protein-based therapeutics. Allozyne will initially focus on developing enhanced formulations of currently approved protein therapeutic products, using the company’s diverse chemistries and proprietary modification technologies. The modifications will significantly improve the efficacy of those protein drugs, resulting in superior patient care and outcomes.

Portfolio Home